Category - Developments

Developments

Kadmon Holdings completes enrollment for registrational GvHD trial

Kadmon Holdings (NYSE:KDMN) completed enrollment for its registrational trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD). cGvHD is a deadly complication of hematopoietic stem cell...

August 14, 2019

Developments

Moleculin Biotech completes enrollment in lymphoma clinical trial

Moleculin Biotech (NASDAQ:MBRX) has completed patient enrollment in its proof-of-concept trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL). WP1220 is a topical treatment designed to inhibit p-STAT3...

August 14, 2019

Developments

Novan completes enrollment in pivotal Phase 3 molluscum contagiosum trial

Novan (NASDAQ:NOVN) has completed patient enrollment in its Phase 3 pivotal trial of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum contagiosum is a viral skin infection that...

August 14, 2019

Developments

Precipio posts continuous improvement in Q2 pathology sales metrics

Precipio (NASDAQ:PRPO) reported results of three key performance metrics that together demonstrate the continued growth and positive impact of the expansion of its sales force in improving pathology sales performance...

August 13, 2019

Developments

Progenics Pharma completes enrollment in Phase 3 prostate cancer detection trial

Progenics Pharmaceuticals (NASDAQ:PGNX) completed enrollment for its Phase 3 study testing the diagnostic performance and clinical impact of 18F-DCFPyL (PyL) in men with recurrent prostate cancer. PyL, a small molecule...

August 6, 2019

Developments

Kane Biotech gets $3.8-million Canadian government funding

Kane Biotech (TSXV:KNE) received $3.8-million in funding from Western Economic Diversification Canada to assist the company in expanding from the animal health sector into the human health sector with DispersinB, a...

August 6, 2019

Developments

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis. Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production...

August 6, 2019

Developments

SELLAS completes enrollment for Phase 2 DCIS trial

SELLAS Life Sciences Group (NASDAQ:SLS) completed enrollment for a Phase 2 study of nelipepimut-S (NPS) in combination with granulocyte macrophage colony stimulating factor (GM-CSF) in women with ductal carcinoma in...

August 6, 2019

Developments

FDA clears Mustang Bio IND for CAR T cell therapy

Mustang Bio (NASDAQ:MBIO) reported that the FDA approved its IND application for MB-102 for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk...

August 6, 2019

Developments

Provention Bio gets FDA breakthrough therapy designation for PRV-031

Provention Bio (NASDAQ:PRVB) received breakthrough therapy designation for PRV-031 for the prevention or delay of Type 1 diabetes (T1D) in at-risk individuals. PRV-031, an anti-CD3 monoclonal antibody also known as...

August 6, 2019

Category - Developments

Subscribe